# A Safety and PK Study of IV Eravacycline

> **NCT03696550** · PHASE1 · COMPLETED · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 19 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Eravacycline (TP-434)

## Key facts

- **NCT ID:** NCT03696550
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2021-03-14
- **Final completion:** 2021-03-19
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696550, "A Safety and PK Study of IV Eravacycline". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03696550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*